Back to Search Start Over

Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer

Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer

Authors :
Levent Naci Ozluoglu
Cem Ozer
Ozlem Ozen
Thomas S. Griffith
Tuba Canpolat
Salih Sanlioglu
Isilay Dogan
Burcak Yoldas
Source :
Head & Neck. 33:1278-1284
Publication Year :
2010
Publisher :
Wiley, 2010.

Abstract

Background. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a death ligand currently under clinical trials for cancer. The molecular profile of TRAIL and TRAIL receptors has not yet been mapped for patients with laryngeal squamous cell carcinoma (SCC) or patients with oral cavity squamous cell carcinoma (OCSCC). Methods. Paraffin-embedded tissues from 60 patients with laryngeal SCC and 14 patients with OCSCC were retrospectively analyzed using immunohistochemistry. Results. An increase in decoy-R1 (DcR1) but a decrease in decoy-R2 (DcR2) expression were observed in patients with laryngeal SCC and in patients with OCSCC compared with control individuals with benign lesions. Clinical and pathologic grading revealed distinctive TRAIL and TRAIL receptor profiles in patients with squamous cell carcinoma of the head and neck (SCCHN). Conclusions. TRAIL and a TRAIL receptor expression profile might be useful to follow-up disease progression by virtue of its connection with clinical staging and pathologic grading in patients with laryngeal SCC. © 2010 Wiley Periodicals, Inc. Head Neck, 2010

Details

ISSN :
10433074
Volume :
33
Database :
OpenAIRE
Journal :
Head & Neck
Accession number :
edsair.doi.dedup.....95fc43d1f6c8973eaae4f7808588c52b
Full Text :
https://doi.org/10.1002/hed.21598